Literature DB >> 2278521

Type I allergic reactions of the middle ear and eustachian tube: an experimental study.

K Tomonaga1, T Chaen, Y Kurono, G Mogi.   

Abstract

To clarify the role of type I allergic reactions in etiology and pathogenesis of otitis media with effusion and to determine whether or not the middle ear is an allergic "shock" organ, we made animal models of nasal allergy in guinea pigs by passive sensitization with serum of homologous animals containing specific IgE antibodies. We also examined the eustachian tube, tympanic cavity (histologically), and tubal function after the induction of type I allergic reactions of the nose. However, the involvement of histologic changes was limited only up to the area near the pharyngeal orifice. The tubal dysfunction evoked by nasal allergic reactions was transient, culminating in no middle ear effusion. Upon direct antigen-challenge into the tympanic cavity, allergic changes were observed in the mucosa lining the tympanic bulla, even though no microscopic effusion was present. Findings of the present study suggest that type I allergic reactions of the nose are not an etiologic factor for otitis media with effusion, although the middle ear is potentially an allergic shock organ.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2278521     DOI: 10.1016/s0385-8146(12)80072-1

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  2 in total

1.  An experimental study of inner ear injury in an animal model of eosinophilic otitis media.

Authors:  Atsushi Matsubara; Hisanori Nishizawa; Akira Kurose; Takashi Nakagawa; Junko Takahata; Akira Sasaki
Journal:  Acta Otolaryngol       Date:  2013-12-23       Impact factor: 1.494

2.  CD11c(+) dendritic cells coexpressing thymic stromal lymphopoietin receptor in animal model of eosinophilic otitis media.

Authors:  Ryutaro Hara; Naomi Kudo; Satoshi Suzuki; Tomoya Miura; Atsushi Matsubara
Journal:  Asia Pac Allergy       Date:  2020-10-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.